Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
Enanta Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: January 17, 2020
Enanta Pharmaceuticals reported fiscal year 2019 executive compensation information on January 17, 2020.
In 2019, five executives at Enanta Pharmaceuticals received on average a compensation package of $2.2M, a 4% increase compared to previous year.
Average pay of disclosed executives at Enanta Pharmaceuticals
Jay R. Luly, Chief Executive Officer, received $4.5M in total, which decreased by 1% compared to 2018. 68% of Luly's compensation, or $3M, was in option awards. Luly also received $337K in non-equity incentive plan, $642K in salary, $458K in stock awards, as well as $19K in other compensation.
For fiscal year 2019, the median employee pay was $260,099 at Enanta Pharmaceuticals. Therefore, the ratio of Jay R. Luly's pay to the median employee pay was 17 to one.
Yat Sun Or, Chief Scientific Officer, received a compensation package of $1.6M, which increased by 7% compared to previous year. 55% of the compensation package, or $890K, was in option awards.
Nathalie Adda, Chief Medical Officer, earned $1.6M in 2019, a 7% increase compared to previous year.
Paul J. Mellett, Chief Financial Officer, received $1.5M in 2019, which increases by 8% compared to 2018.
Nathaniel S. Gardiner, General Counsel, earned $1.5M in 2019, a 9% increase compared to previous year.
Enanta Pharmaceuticals' fiscal year ends on September 30.
Related executives
You may also like
Source: SEC filing on January 17, 2020.